Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
11
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.
days to go:
Expired
investment:
£394,680
Steve Grindrod Amplification (SGA) creates guitar amplifiers designed by Steve Grindrod, arguably one of the best electric guitar amp designers in the world. SGA already have over 50 global distributors ready to go once they have the funds for their marketing campaign.
days to go:
Expired
investment:
£3,300
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go:
Expired
investment:
£5,083,686
B-North is a financial technology bank combining cloud-native technology with face-to-face relationship banking to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. It argues that it delivers cash to SMEs faster than the competition by combining its lending origination platform with a locally delivered servicing and relationship model overseen by experienced bankers. B-North asserts that it is engaging in a positive dialogue with several potential investors with a committed investment now standing at £18.6 million since June 2020. The company has also raised a seed capital of over £6.8 million that includes a six-figure investment from the Greater Manchester Combined Authority to establish its core team and create both the lending and deposit-taking platforms. The company will use the investment to provide a cash runway to the end of Q2 2021 as the team finalises its Series A round and secures its banking license.
days to go:
Expired
investment:
£883,835
